Pharmacological inhibition on the ataxia telangiectasia and Rad3-linked protein serine/threonine kinase (ATR; also referred to as FRAP-similar protein (FRP1)) has emerged for a promising approach for most cancers therapy that exploits artificial lethal interactions with proteins involved in DNA harm maintenance, overcomes resistance to other therapies and boosts antitumour immunity. https://cicilk665myi4.blog-a-story.com/profile